Lars Edvinsson Selected Research

5-HT1B Serotonin Receptor

1/2013	Permanent distal occlusion of middle cerebral artery in rat causes local increased ETB, 5-HT₁B and AT₁ receptor-mediated contractility downstream of occlusion.
4/2011	Improvement in neurological outcome and abolition of cerebrovascular endothelin B and 5-hydroxytryptamine 1B receptor upregulation through mitogen-activated protein kinase kinase 1/2 inhibition after subarachnoid hemorrhage in rats.
7/2003	Subarachnoid hemorrhage-induced upregulation of the 5-HT1B receptor in cerebral arteries in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lars Edvinsson Research Topics

Disease

96	Migraine Disorders (Migraine) 10/2022 - 01/2002
32	Brain Ischemia (Cerebral Ischemia) 01/2022 - 09/2002
32	Headache (Headaches) 01/2022 - 05/2002
20	Pain (Aches) 10/2019 - 09/2002
19	Stroke (Strokes) 12/2022 - 04/2006
19	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 03/2019 - 01/2002
17	Cardiovascular Diseases (Cardiovascular Disease) 02/2021 - 01/2004
15	Inflammation (Inflammations) 12/2020 - 07/2004
10	Ischemia 01/2022 - 06/2009
10	Ischemic Stroke 01/2022 - 04/2004
9	Cluster Headache (Cluster Headaches) 01/2020 - 05/2002
7	Infarction (Infarctions) 12/2022 - 01/2007
7	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2022 - 01/2007
7	Heart Failure 06/2020 - 01/2004
7	Angina Pectoris 02/2013 - 06/2006
6	Myocardial Ischemia (Ischemic Heart Diseases) 12/2018 - 01/2004
6	Atherosclerosis 02/2014 - 08/2002
5	Hypertension (High Blood Pressure) 01/2018 - 12/2004
4	Vascular Diseases (Vascular Disease) 06/2012 - 02/2002
3	Myocardial Infarction 10/2022 - 11/2007
3	Ganglion Cysts (Ganglion) 01/2019 - 01/2012
3	Intracranial Vasospasm 04/2004 - 01/2002
2	Headache Disorders (Headache Syndromes) 01/2019 - 01/2019
2	Reperfusion Injury 10/2017 - 01/2017
2	Neurogenic Inflammation 01/2017 - 12/2010
2	Obesity 02/2016 - 01/2016

Drug/Important Bio-Agent (IBA)

57	Calcitonin Gene-Related PeptideIBA 10/2022 - 01/2002
35	Endothelins (Endothelin)IBA 02/2021 - 01/2002
30	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 10/2022 - 05/2002
24	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 10/2022 - 01/2002
21	NeuropeptidesIBA 02/2022 - 05/2002
15	Tryptamines (Triptans)IBA 02/2022 - 05/2002
13	Peptides (Polypeptides)IBA 01/2022 - 07/2005
12	Vasoconstrictor AgentsIBA 01/2022 - 12/2004
12	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA 10/2020 - 11/2011
12	U 0126 (UO 126)IBA 01/2019 - 04/2007
11	Endothelin Receptors (Endothelin Receptor)IBA 10/2017 - 05/2003
10	Monoclonal AntibodiesIBA 10/2022 - 01/2017
10	Serotonin (5 Hydroxytryptamine)IBA 02/2022 - 12/2007
10	SmokeIBA 02/2021 - 12/2008
9	Pharmaceutical PreparationsIBA 01/2021 - 01/2005
9	Vasodilator Agents (Vasodilators)IBA 03/2019 - 07/2005
9	Messenger RNA (mRNA)IBA 01/2019 - 01/2004
9	Endothelin-1 (Endothelin 1)IBA 01/2018 - 09/2002
9	Angiotensin IIIBA 01/2018 - 04/2004
8	Proteins (Proteins, Gene)FDA Link 12/2022 - 01/2007
7	Angiotensin Receptors (Angiotensin II Receptor)IBA 02/2010 - 10/2004
6	AntibodiesIBA 12/2019 - 08/2015
6	Neurotransmitter Agents (Neurotransmitter)IBA 01/2019 - 06/2003
6	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 08/2017 - 12/2012
6	telcagepantIBA 09/2014 - 02/2008
5	CytokinesIBA 01/2020 - 02/2010
5	fremanezumabIBA 12/2019 - 11/2015
5	Adenylyl Cyclases (Adenylyl Cyclase)IBA 11/2018 - 12/2014
5	AngiotensinsIBA 01/2013 - 10/2004
5	Mitogen-Activated Protein KinasesIBA 12/2012 - 01/2008
4	erenumabIBA 12/2019 - 01/2018
4	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 01/2017 - 05/2002
4	Thromboxane Receptors (Thromboxane Receptor)IBA 01/2017 - 02/2010
4	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 01/2016 - 07/2006
4	ThromboxanesIBA 01/2013 - 02/2008
4	Type 1 Angiotensin ReceptorIBA 05/2009 - 04/2004
4	olcegepantIBA 02/2008 - 01/2002
3	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 12/2022 - 10/2011
3	Biological ProductsIBA 01/2022 - 12/2017
3	salicylhydroxamic acid (SHAM)IBA 01/2022 - 09/2002
3	Oxytocin (Pitocin)FDA LinkGeneric 10/2021 - 02/2020
3	Substance PIBA 01/2021 - 07/2014
3	Pituitary Adenylate Cyclase-Activating Polypeptide ReceptorsIBA 01/2020 - 08/2018
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 07/2006
3	Protein Kinases (Protein Kinase)IBA 01/2019 - 05/2014
3	Islet Amyloid PolypeptideIBA 01/2016 - 07/2005
3	Sumatriptan (Imigran)FDA LinkGeneric 12/2014 - 01/2004
3	AdrenomedullinIBA 01/2014 - 07/2005
3	5-HT1B Serotonin ReceptorIBA 01/2013 - 07/2003
3	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2013 - 11/2007
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2011 - 12/2007
3	Endothelin B ReceptorIBA 03/2010 - 07/2004
2	purinoceptor P2Y6IBA 01/2022 - 05/2003
2	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2022 - 10/2021
2	Uridine Diphosphate (UDP)IBA 01/2022 - 02/2002
2	Hormones (Hormone)IBA 10/2021 - 02/2020
2	rimegepant sulfateIBA 01/2021 - 01/2019
2	RNA (Ribonucleic Acid)IBA 12/2020 - 07/2007
2	ubrogepantIBA 01/2020 - 01/2018
2	MicroRNAs (MicroRNA)IBA 11/2019 - 02/2015
2	Purinergic Receptors (Receptors, Purine)IBA 10/2019 - 01/2014
2	Retinaldehyde (Retinal)IBA 01/2019 - 01/2016
2	galcanezumabIBA 01/2019 - 01/2018
2	Excitatory Amino Acid AntagonistsIBA 01/2019 - 12/2012
2	eptinezumabIBA 01/2019 - 01/2018
2	Adenosine Triphosphate (ATP)IBA 12/2018 - 07/2005
2	Carbachol (Carbastat)FDA Link 01/2018 - 02/2013
2	sarafotoxins s6IBA 01/2018 - 07/2004
2	Thromboxane A2 (A2, Thromboxane)IBA 01/2017 - 02/2010
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2015 - 05/2009
2	MitogensIBA 01/2015 - 12/2007
2	Serotonin ReceptorsIBA 12/2014 - 01/2012

Therapy/Procedure

28	Therapeutics 01/2022 - 06/2006
5	Counterpulsation (External Counterpulsation) 02/2013 - 06/2006